Dirk Dressler
#117,395
Most Influential Person Now
German neurologist and psychiatrist
Dirk Dressler's AcademicInfluence.com Rankings
Dirk Dresslermedical Degrees
Medical
#1904
World Rank
#2287
Historical Rank
Neurology
#206
World Rank
#281
Historical Rank
Download Badge
Medical Biology
Why Is Dirk Dressler Influential?
(Suggest an Edit or Addition)According to Wikipedia, Konrad Karl Erich Bodo Wilhelm Dirk Dressler is a German neurologist and psychiatrist. He is Full Professor of Neurology at Hannover Medical School. His research focus is neurological movement disorders and the development and introduction of the botulinum toxin therapy.
Dirk Dressler's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. (1989) (924)
- Botulinum toxin: mechanisms of action. (2005) (259)
- Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes (2003) (236)
- Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. (2013) (226)
- Facing depression with botulinum toxin: a randomized controlled trial. (2012) (223)
- Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) (208)
- Pharmacology of botulinum toxin: differences between type A preparations (2006) (176)
- Autonomic Side Effects of Botulinum Toxin Type B Treatment of Cervical Dystonia and Hyperhidrosis (2002) (172)
- Botulinum Toxin: Mechanisms of Action (2005) (169)
- Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. (2007) (160)
- Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease (2002) (158)
- Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc® (2006) (157)
- Pharmacology of therapeutic botulinum toxin preparations (2007) (151)
- The syndrome of painful legs and moving toes (1994) (151)
- Brain parenchyma sonography detects preclinical parkinsonism (2004) (142)
- Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy (2004) (135)
- GPi-DBS may induce a hypokinetic gait disorder with freezing of gait in patients with dystonia (2011) (135)
- Effect of digital nerve stimuli on responses to electrical or magnetic stimulation of the human brain. (1992) (132)
- Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence (2009) (130)
- Clinical applications of botulinum toxin. (2012) (130)
- Further observations on the facilitation of muscle responses to cortical stimulation by voluntary contraction. (1991) (120)
- Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease (2005) (117)
- Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy (2004) (113)
- On muscle spindles, dystonia and botulinum toxin (2010) (109)
- Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? (2010) (101)
- Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia. (2003) (96)
- Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease (2007) (91)
- Botulinum toxin type B for treatment of axillar hyperhidrosis (2002) (91)
- Prospective study of selective peripheral denervation for botulinum-toxin resistant patients with cervical dystonia. (2001) (90)
- Transcranial electric and magnetic stimulation of the leg area of the human motor cortex: single motor unit and surface EMG responses in the tibialis anterior muscle. (1993) (87)
- Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure (2003) (85)
- Routine use of Xeomin® in patients previously treated with Botox®: long term results (2009) (84)
- Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia (2006) (84)
- Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. (1993) (81)
- Higher prevalence of obsessive-compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm. (1998) (74)
- Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay (2011) (73)
- Clinical Features of Antibody-Induced Complete Secondary Failure of Botulinum Toxin Therapy (2002) (71)
- Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. (2013) (71)
- Electromyographic Quantification of the Paralysing Effect of Botulinum Toxin in the Sternocleidomastoid Muscle (2000) (71)
- Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy (2000) (70)
- Changes of transcranially evoked motor responses in man by midazolam, a short acting benzodiazepine (1989) (69)
- New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3) (2015) (65)
- Rapid rate transcranial magnetic stimulation--a safety study. (1997) (64)
- Botulinum toxin in the management of chronic migraine: clinical evidence and experience (2017) (62)
- Five‐year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins (2012) (61)
- Clinical use of non-a botulinum toxins: botulinum toxin type B (2006) (60)
- Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity (2017) (58)
- Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives (2014) (56)
- Comparing Botox® and Xeomin® for axillar hyperhidrosis (2010) (55)
- Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement (2015) (54)
- Antibody‐Induced Failure of Botulinum Toxin A Therapy in Cosmetic Indications (2010) (53)
- A hexanucleotide repeat modifies expressivity of X‐linked dystonia parkinsonism (2019) (52)
- Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting (2016) (52)
- Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport® (2015) (51)
- The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing (2010) (51)
- Antibody-Induced Botulinum Toxin Therapy Failure: Can It Be Overcome by Increased Botulinum Toxin Doses? (2002) (51)
- Botulinum toxin antibody testing: Comparison between the mouse protection assay and the mouse lethality assay (2000) (48)
- Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy (2018) (48)
- Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox® or Dysport® (2010) (48)
- Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity (2009) (47)
- Clinical use of non-a botulinum toxins: Botulinum toxin type C and botulinum toxin type F (2006) (47)
- Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy (2002) (46)
- Safety aspects of incobotulinumtoxinA high-dose therapy (2015) (45)
- Impaired Quality of Life and Need for Palliative Care in a German Cohort of Advanced Parkinson’s Disease Patients (2018) (45)
- Botulinum toxin treatment of axial and cervical dystonia (2007) (45)
- Severe tardive dystonia: Treatment with continuous intrathecal baclofen administration (1997) (42)
- Complete secondary botulinum toxin therapy failure in blepharospasm (2000) (42)
- Botulinum toxin drugs: brief history and outlook (2016) (41)
- ERRATA : DIRECTION OF CURRENT IN MAGNETIC STIMULATING COILS USED FOR PERCUTANEOUS ACTIVATION OF BRAIN, SPINAL CORD AND PERIPHERAL NERVE (1990) (41)
- Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia (2013) (41)
- Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. (2005) (41)
- The automated FADU-assay, a potential high-throughput in vitro method for early screening of DNA breakage. (2011) (41)
- Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects (2015) (40)
- Safety aspects of transcranial brain stimulation in man tested by single photon emission-computed tomography (1990) (39)
- Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) (2013) (39)
- Botulinum Toxin Antibody Testing: Comparison between the Immunoprecipitation Assay and the Mouse Diaphragm Assay (2001) (39)
- Antibody-Induced Failure of Botulinum Toxin Type B Therapy in de novo Patients (2004) (39)
- Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations (2006) (39)
- The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans (2000) (38)
- Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity The TOWER study (36)
- Abnormal interaction between vestibular and voluntary head control in patients with spasmodic torticollis. (2001) (36)
- Neural mechanisms underlying cognitive inflexibility in Parkinson's disease (2016) (35)
- Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism (2016) (35)
- Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia (2002) (35)
- Increased volume and impaired function: the role of the basal ganglia in writer’s cramp (2014) (33)
- Diagnosis and management of acute movement disorders (2005) (33)
- Meta-analytical and electrophysiological evidence for executive dysfunction in primary dystonia (2016) (32)
- Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force (2016) (30)
- Mouse diaphragm assay for detection of antibodies against botulinum toxin type B (2005) (30)
- Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia (2004) (30)
- Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy (2017) (29)
- Immunological aspects of botulinum toxin therapy (2017) (29)
- Botulinum toxin for treatment of dystonia (2010) (29)
- Botulinum toxin therapy of writer's cramp (2006) (27)
- New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm. (2004) (27)
- Dopaminergic modulation of performance monitoring in Parkinson’s disease: An event-related potential study (2017) (26)
- Tonic contractions of the tensor tympani muscle: a key to some non-specific middle ear symptoms? Hypothesis and data from temporal bone experiments (2005) (26)
- Strategies for treatment of dystonia (2016) (26)
- Manual Of Botulinum Toxin Therapy 2nd Ed. (2014) (25)
- Botulinum toxin type B de novo therapy of cervical dystonia (2005) (25)
- Machado-Joseph disease presenting as severe generalised dystonia in a German patient (1999) (24)
- Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system (2013) (24)
- Assessment of Substantia Nigra Echogenicity in German and Filipino Populations Using a Portable Ultrasound System (2012) (24)
- Conventional versus neutral positioning in central neurological disease: a multicenter randomized controlled trial. (2015) (24)
- Cognitive Flexibility in Primary Dystonia (2016) (23)
- Frequency and risk factors of antibody-induced secondary failure of botulinum neurotoxin therapy (2020) (23)
- Subclinical Myasthenia Gravis causing increased sensitivity to botulinum toxin therapy (2010) (23)
- X‐linked Dystonia‐Parkinsonism manifesting in a female patient due to atypical turner syndrome (2013) (23)
- Quality of life and costs of spasticity treatment in German stroke patients (2016) (23)
- Sonographic detection of basal ganglia abnormalities in spasmodic dysphonia (2014) (22)
- Absence of congruency sequence effects reveals neurocognitive inflexibility in Parkinson's disease (2013) (21)
- Attention shifting in Parkinson's disease: an analysis of behavioral and cortical responses. (2014) (21)
- Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity (2018) (20)
- Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity (2021) (20)
- Changes of somatosensory evoked potentials in man as correlates of transcortical reflex mediation? (1984) (20)
- Transcranial sonography findings in welding‐related Parkinsonism in comparison to Parkinson's disease (2008) (20)
- Botulinum toxin drugs: future developments (2008) (20)
- Nonprimary dystonias. (2011) (20)
- Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study (2015) (20)
- Sonographic Alteration of Lenticular Nucleus in Focal Task-Specific Dystonia of Musicians (2011) (20)
- Asparagus and jejunal-through-PEG: an unhappy encounter in intrajejunal levodopa infusion therapy. (2011) (19)
- Association of Motor and Cognitive Symptoms with Health-Related Quality of Life and Caregiver Burden in a German Cohort of Advanced Parkinson's Disease Patients (2020) (18)
- [Pharmacology of botulinum toxin drugs]. (2012) (18)
- Botulinum toxin therapy in the SARS-CoV-2 pandemic: patient perceptions from a German cohort (2020) (17)
- Intrathecal Baclofen therapy in Germany: Proceedings of the IAB—Interdisciplinary Working Group for Movement Disorders Consensus Meeting (2015) (17)
- [Pharmacological aspects of therapeutic botulinum toxin preparations]. (2006) (17)
- Overactive bladder in Parkinson's disease: alteration of brainstem raphe detected by transcranial sonography (2006) (16)
- Validating the Parkinson’s disease caregiver burden questionnaire (PDCB) in German caregivers of advanced Parkinson’s disease patients (2019) (16)
- Sensory Alterations in Patients with Isolated Idiopathic Dystonia: An Exploratory Quantitative Sensory Testing Analysis (2017) (16)
- Alexithymia Is Associated with Reduced Quality of Life and Increased Caregiver Burden in Parkinson’s Disease (2020) (16)
- Safety of botulinum toxin short interval therapy using incobotulinumtoxin A (2017) (15)
- Polyradiculoneuritis following botulinum toxin therapy (1990) (15)
- Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study (2020) (15)
- Differential effect of cutanoeous stimuli on responses to electrical or magnetic stimulation of the humain brain (1988) (15)
- Autonomic side effects of botulinum toxin type B therapy. (2004) (15)
- Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study (2019) (14)
- Altered Neurometabolic Profile in Early Parkinson's Disease: A Study With Short Echo-Time Whole Brain MR Spectroscopic Imaging (2019) (14)
- Botulinum toxin therapy: reduction of injection site pain by pH normalisation (2016) (14)
- Dyskinesias possibly induced by norpseudoephedrine (2004) (14)
- New formulation of BOTOX® (2004) (13)
- Altered brain activation in a reversal learning task unmasks adaptive changes in cognitive control in writer's cramp (2015) (13)
- [Anti-inflammatory action of a hyaluronic acid-chondroitin sulfate preparation in an in vitro bladder model]. (2009) (13)
- Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia (2014) (13)
- Frontalis suspension surgery to treat patients with blepharospasm and eyelid opening apraxia: long-term results (2017) (13)
- Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson’s Disease (2020) (13)
- Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis (2019) (12)
- [Botulinum toxin in therapy of craniocervical dystonia]. (1989) (12)
- [Taste disorders following tonsillectomy. A rare complication of a common operation]. (1989) (12)
- Lack of mutations in the epsilon‐sarcoglycan gene in patients with different subtypes of primary dystonias (2004) (12)
- Magnetic stimulation of the human brain can activate different neuronal elements when the magnetic field direction is reversed (1988) (12)
- IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®) (2014) (11)
- Botulinum toxin therapy in patients with oral anticoagulation: is it safe? (2018) (11)
- Cabergoline can increase penile erections and libido. (2002) (11)
- An enzyme‐linked immunosorbent assay for detection of botulinum toxin‐antibodies (2014) (11)
- Frontalis suspension surgery to treat patients with essential blepharospasm and apraxia of eyelid opening-technique and results (2014) (11)
- Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures (2015) (11)
- Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine (2014) (11)
- In Vitro Activation of eNOS by Mangifera indica (Careless™) and Determination of an Effective Dosage in a Randomized, Double-Blind, Human Pilot Study on Microcirculation (2015) (11)
- Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox® doses (2013) (10)
- The Dystonia Discomfort Scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia (2014) (10)
- New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia (2009) (10)
- Comparing incobotulinumtoxinA (Xeomin®) and onabotulinumtoxinA (Botox®): identical potency labelling in the hemidiaphragm assay (2018) (10)
- Therapeutically relevant features of botulinum toxin drugs. (2020) (10)
- Can intravenous immunoglobulin improve antibody‐mediated botulinum toxin therapy failure? (2000) (10)
- The Application of Normal, SV40 T-antigen-immortalised and Tumour-derived Oral Keratinocytes, under Serum-free Conditions, to the Study of the Probability of Cancer Progression as a Result of Environmental Exposure to Chemicals (2007) (10)
- New insights into the genetics of X-linked dystonia-parkinsonism ( XDP , DYT 3 ) (2015) (10)
- Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism. (2017) (10)
- [Clinical relevance of botulinum toxin antibodies]. (2008) (10)
- Bilateral limb dystonia due to chronic subdural hematoma. (1990) (10)
- Reconstituting botulinum toxin drugs: shaking, stirring or what? (2016) (10)
- Botulinum Toxin for Treatment of Jaw Opening Dystonia in Hallervorden-Spatz Syndrome (2001) (10)
- Botulinum toxin: mechanisms of action. (2005) (10)
- Botulinum toxin therapy of hemifacial spasm: bilateral injections can reduce facial asymmetry (2018) (10)
- Long-term stability of reconstituted incobotulinumtoxinA: how can we reduce costs of botulinum toxin therapy? (2017) (9)
- [Botulinum toxin: from drug to poison]. (2009) (9)
- Central motor conduction time to bulbocavernosus muscle: evaluation by magnetic brain stimulation and testing of bulbocavernosus reflex (1990) (9)
- Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study (2020) (9)
- Severe familial paroxysmal exercise-induced dyskinesia (2014) (8)
- [Botulism caused by consumption of smoked salmon]. (2005) (8)
- Efficacy of incobotulinumtoxinA for the treatment of adult lower-limb post-stroke spasticity, including pes equinovarus. (2020) (8)
- Botulinum Toxin Therapy Manual for Dystonia and Spasticity (2016) (8)
- Hyperkinesias after hypoglossofacial nerve anastomosis--treatment with botulinum toxin. (1991) (8)
- Treatment of focal hand dystonia (2009) (7)
- Advance Directives of German People with Parkinson's Disease Are Unspecific in regard to Typical Complications (2019) (7)
- Slow pre-movement cortical potentials do not reflect individual response to therapy in writer’s cramp (2009) (7)
- New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia (2006) (6)
- [The role of magnetic stimulation in diagnosis of the peripheral nervous system]. (1988) (6)
- Mutation at the SCA17 locus is not a common cause of primary dystonia (2004) (6)
- Interdisziplinärer Arbeitskreis Bewegungsstörungen (IAB): an interdisciplinary working group for promoting multimodal therapy of movement disorders (2013) (6)
- Clinical Pharmacology of Botulinum Toxin Drugs. (2020) (6)
- Botulinum toxin therapy of dystonia (2020) (6)
- Intratympanic application of botulinum toxin: experiments in guinea pigs for excluding ototoxic effects (2008) (6)
- Treatment of persistent hemiballism with botulinum toxin type A (2000) (6)
- Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA (2020) (6)
- Impaired heart rate variability in cervical dystonia is associated to depression (2017) (5)
- 99mTc-Hexamethylpropylene amine oxime SPECT and X-ray CT in acute cerebral ischaemia (1990) (5)
- Expression of retinoid-related genes in serum-free cultures of normal, immortalized and malignant human oral keratinocytes. (2002) (5)
- Brissaud-Sicard syndrome caused by a diffuse brainstem glioma. A rare differential diagnosis of hemifacial spasm (2014) (5)
- Comparing biological potencies of Botox and Dysport with a mouse diaphragm model may mislead (1998) (5)
- Lantox—The Chinese Botulinum Toxin Drug—Complete English Bibliography and Comprehensive Formalised Literature Review (2021) (5)
- Basic and therapeutic aspects of neurotonins (2004) (4)
- [An improved model of a catheterised human bladder for screening bactericidal agents]. (2008) (4)
- Effects of therapeutic positioning on vital parameters in patients with central neurological disorders: a randomised controlled trial. (2015) (4)
- Gasperini's Syndrome: Its Neuroanatomical Basis Now and Then (2012) (4)
- A brief history of neurological botulinum toxin therapy in Germany (2017) (4)
- Manual of Botulinum Toxin Therapy: Spasticity (2009) (4)
- [Antibody-induced failure of botulinum toxin therapy]. (2003) (4)
- Botulinumtoxintherapie in der Rehabilitationsneurologie (1996) (4)
- Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay (2019) (4)
- Dopamine DRD2 polymorphism (DRD2/ANNK1-Taq1A) is not a significant risk factor in writer’s cramp (2016) (4)
- More than hemifacial spasm? A case of unilateral facial spasms with systematic review of red flags (2019) (4)
- Dopaminergic modulation of novelty repetition in Parkinson’s disease: A study of P3 event-related brain potentials (2020) (4)
- Clinical Relevance of Immunoresistance to Botulinum Therapy (2016) (4)
- IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study (2019) (4)
- Introductory Chapter: Botulinum Toxin Type A Therapy in Dystonia and Spasticity - What are Current Practical Applications? (2016) (4)
- The epidemiology of dystonia: the Hannover epidemiology study (2022) (3)
- [Fractionated determination of central motor conduction times using stimulation of the cortex, spinal tract and spinal nerve roots: possibilities and limits]. (1988) (3)
- Nicotine nasal spray is not reliable treatment for blepharospasm: Results of a pilot study (1998) (3)
- La toxina botulínica tipo B: dónde estamos (2002) (3)
- [Dystonia as the cause of pharyngolaryngeal motility disorders]. (1995) (3)
- Strategies to decrease injection site pain in botulinum toxin therapy (2016) (3)
- Botulinum toxin therapy: past, present and future developments (2022) (3)
- Rehabilitation of Dystonia (2017) (3)
- Botulinum toxin to suppress hyperkinesias after hypoglossal-facial nerve anastomosis (2004) (3)
- Botulinum toxin type D blocks autonomic cholinergic synapses in humans: discussion of a potential therapeutic use (2019) (3)
- Botulinum toxin in myotonia congenita: it does not help against rigidity and pain (2014) (3)
- Identification of Shiga-Toxigenic Escherichia coli outbreak isolates by a novel data analysis tool after matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (2017) (3)
- Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study (2018) (3)
- OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine. (2019) (3)
- Albert Schweitzer: a patient with writer's cramp. (2012) (2)
- Manual of Botulinum Toxin Therapy: Immunological properties of botulinum toxins (2009) (2)
- [Treatment goals in patients with post-stroke upper limb spasticity following injection of botulinum toxin A : Results of the German-Austrian subgroup of the ULIS-II study]. (2019) (2)
- Conflict adaptation and related neuronal processing in Parkinson’s disease (2021) (2)
- Neuritis nervi optici und Multiple Sklerose (2001) (2)
- [Initial experiences with clinical use of botulinum toxin type B]. (2002) (2)
- Contents Vol. 45, 2001 (2001) (2)
- Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum toxin therapy (2017) (2)
- [Transcranial brain stimulation. Methods and results]. (1988) (2)
- Selective peripheral denervation with posterior primary ramisectomy is useful for botulinum toxin resistant patients with cervical dystonia: Results of a prospective study (1999) (2)
- Comparing incobotulinumtoxina (Xeomin) and onabotulinumtoxina (Botox): Identical potency labeling in the hemidiaphragm assay (2016) (2)
- Manual of Botulinum Toxin Therapy: Botulinum toxin: history of clinical development (2009) (2)
- The development of an epileptogenic focus (1989) (2)
- Significance of HMPAO-SPECT in the early diagnosis and followup of acute cerebral ischemia—Comparison to CCT (1989) (2)
- Manual of Botulinum Toxin Therapy: Pharmacology of botulinum toxin drugs (2009) (2)
- The Immunology of Botulinum Toxin Therapy: A Brief Summary. (2022) (1)
- Neuropsychiatric Disturbances in Dystonia (2015) (1)
- 68. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) (2015) (1)
- Clinical Use of Botulinum Neurotoxin: Autonomic Conditions (2014) (1)
- [Use of botulinum toxin the the treatment of muscle pain]. (2003) (1)
- Communication calendar for botulinum toxin therapy of spasticity in an outpatient setting (2013) (1)
- 151. Botulinum neurotoxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures (2015) (1)
- Antibody-induced failure of botulinum toxin therapy: Restart with incobotulinumtoxina offers a new opportunity (2016) (1)
- Botulinum Toxin Type B: Where Do We Stand? (2001) (1)
- Long-term ef fi cacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity : a prospective , non-interventional , open-label , parallel-group study (2015) (1)
- 64. Botulinum neurotoxin therapy of cervical dystonia: duration of therapeutic effects (2015) (1)
- 276 EFFECT OF GLOBUS PALLIDUS INTERNUS (GPI) AND/OR PEDUNCULOPONTINE NUCLEUS (PPN) DBS ON POSTURE AND GAIT IGNITION IN ADVANCED PARKINSON'S DISEASE (2010) (1)
- Botulinum toxin dosing in arm muscles: contextual factors (2021) (1)
- [Gilles-de-la-Tourette syndrome]. (1992) (1)
- Erratum to: ‘Quality of life and costs of spasticity treatment in German stroke patients’ (2016) (1)
- [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement]. (2008) (1)
- Dystonia Europe: Hamburg 2008 (2010) (1)
- [Botulinum toxin--the dose controls the poison. A historical sketch]. (2002) (1)
- Observations on the facilitation of muscle responses to cortical stimulation by voluntary effort (1990) (1)
- Do complexing proteins provide mechanical protection for botulinum neurotoxins? (2019) (1)
- 63. Botulinum neurotoxin therapy: reduction of injection site pain by pH normalization (2015) (1)
- P 78 Involvement of the subthalamic nucleus in the maintenance of cognitive flexibility – Evidence from local field potential recordings (2017) (1)
- Medicine and the Pharmaceutical Industry (1963) (1)
- Chapter 33 – Comparative Clinical Trials of Botulinum Toxins (2009) (1)
- Botulinum toxin therapy in the presence of anticoagulation: Hematoma frequency (2013) (1)
- 22 – Orofacial movement impairments in cerebellar dysarthria: a kinematic analysis with electromagnetic articulography (1990) (1)
- Clinical Relevance of Immunoresistance to Botulinum Therapy Clinical Relevance of Immunoresistance to Botulinum Therapy (2016) (0)
- Dose titration of incobotulinumtoxinA for treatment of multifocal upper- and lower limb spasticity (2018) (0)
- 3.004 Dystonia (2007) (0)
- Comparing hengli® with onabotulinumtoxinA and incobotulinumtoxinA: Identical potency labeling in the mouse diaphragm assay (2018) (0)
- Why We Need a Close Cooperation between Russian and European Medicine (2021) (0)
- Long-term treatment of chronic migraine with onabotulinumtoxinA: Efficacy, quality of life, and tolerability in a real-life setting (2016) (0)
- IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis (2018) (0)
- INTRAMUSCULAR BOTULINUM TOXIN INJECTIONS AS A NEW TREATMENT FOR DYSKINETIC SYNDROMES (1992) (0)
- Conflict adaptation and related neuronal processing in Parkinson’s disease (2021) (0)
- Dystonia treated with botulinum toxin: Quality of life and caregiver burden (2018) (0)
- The conflict adaptation effect in Parkinson's disease (2012) (0)
- Immunological properties of botulinum neurotoxins (2014) (0)
- O104:H4 outbreak and non outbreak E. coli strain identification by mass spectrometry: Differentiation of the two groups using ABOS, a new software tool (2015) (0)
- [Current outlook on botulinum toxin medications]. (2007) (0)
- Assessment of nanomaterial induced DNA strand breaks using automated FADU technique in vitro (2017) (0)
- [Apomorphine in the treatment of Parkinson's Disease]. (2005) (0)
- Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations (2022) (0)
- Flanker Task Performance in Isolated Dystonia (Blepharospasm): A Focus on Sequential Effects (2020) (0)
- Relevance of Immunoresistance to Botulinum Therapy (2018) (0)
- 66. Mouse diaphragm assay confirms identical potency labeling for onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) (2015) (0)
- Long-term treatment with botulinumtoxin type A in non-dystonic facial spasms (2009) (0)
- A brief history of neurologic botulinum toxin therapy in Germany (2018) (0)
- Comprar Manual Of Botulinum Toxin Therapy 2nd Ed. | Daniel Truong | 9781107025356 | (2014) (0)
- Support for an hypothesis linking Alzheimer`s disease and Down syndrome (1994) (0)
- 176. The ComCal to facilitate the communication between physicians and physiotherapists in botulinum neurotoxin therapy of spasticity (2015) (0)
- NanoColloids: A New Method for Solubilization of Lipophilic Substances Used in Cell Culture (2001) (0)
- Contrarian Botox pioneer remembered (2022) (0)
- Foreward (2006) (0)
- Prospective, single-arm, dose-titration study of incobotulinumtoxinA (Xeomin; up to 800 U) for treatment of upper- and lower-limb spasticity (2016) (0)
- IncobotulinumtoxinA (Xeomin) treatment Improves quality of Life of patients with upper and lower limb spasticity (2016) (0)
- Antigenicity of botulinum toxin drugs (2013) (0)
- Folate bioavailability in reconstructed skin models and effects of folate in a monolayer wound healing assay. Approaches on topic application (2021) (0)
- Poster 274 Botulinum Toxin Therapy of Cervical Dystonia (CD): Duration of Therapeutic Effects (2012) (0)
- Some Thoughts from Your Publisher (2002) (0)
- Botulinum neurotoxin applications in ophthalmology (2014) (0)
- Parkinson's Disease Caregiver Burden Questionnaire--German Version (2020) (0)
- O-29 - Botulinum Neurotoxin for Treatment of Depression (2012) (0)
- Hengli®: pharmacology and formalized clinical review of the Chinese botulinum toxin drug (2018) (0)
- Incobotulinumtoxina treatment improves quality of life of patients with upper- and lower-limb spasticity (2018) (0)
- Automated method to quantify formation and repair of DNA strand breaks (2010) (0)
- Botulinum toxin therapy of dystonia. (2020) (0)
- 69. Assessing antibodies to botulinum toxin (2015) (0)
- Free communicationAre there evoked potential correlates of a trans-cortical reflex ? (1983) (0)
- Treatment of plantar fasciitis with botulinum neurotoxins (2014) (0)
- Future trends in botulinum toxin drug development (1999) (0)
- Manual of Botulinum Toxin Therapy: Frontmatter (2009) (0)
- Efficacy of incobotulinumtoxin a in treatment of lower-limb spasticity, including pes equinovarus, in adults (2018) (0)
- IncobotulinumtoxinA for hypersalivation in ALS patients (2016) (0)
- Manual of Botulinum Toxin Therapy: Preface (2009) (0)
- Dose titration of incobotulinumtoxinA for the treatment of multifocal upper- and lower-limb spasticity (2018) (0)
- Effects of clozapine on CSF homovanillic acid in spasmodic torticollis (2006) (0)
- The conflict adaptation effect in Parkinson's disease: a study with EEG (2013) (0)
- [Botulinum toxin therapy in rehabilitation neurology]. (1996) (0)
- Foreword – Alan B. Scott (2009) (0)
- [Narcolepsy syndrome--clinical aspects, diagnosis, therapy]. (1989) (0)
- P225-eSafety aspects of incobotulinumtoxinA high dose therapy (2014) (0)
- Abstracts of the Third International Congress on Treatment of Dystonia, 4–7 May 2016, Hannover, Germany (2016) (0)
- Bad Data Do Not Make Good Studies (2004) (0)
- Efficacy of IncobotulinumtoxinA In The Treatment Of Shoulder Spasticity (P4.037) (2017) (0)
- 83. Use of concomitant therapies in real-life clinical management of patients with poststroke upper limb spasticity treated with botulinum toxin: German-Austrian subgroup of the ULIS II study (2015) (0)
- Clinical Pharmacology of Apomorphine (2011) (0)
- Erratum to: Strategies for treatment of dystonia (2016) (0)
- Botulinum neurotoxin in the gastrointestinal tract (2014) (0)
- Poster 130 Sustained Efficacy of IncobotulinumtoxinA (XEOMIN; botulinum neurotoxin type A, free from accessory proteins) in Cervical Dystonia Demonstrated by Investigator‐ and Patient‐rated Outcomes (2011) (0)
- Potency of botulinum toxin drugs: test systems and labelling (2022) (0)
- Subject Index Vol. 45, 2001 (2001) (0)
- Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism (2016) (0)
- C31 EMG in the treatment with botulinum toxin (2008) (0)
- 65. Efficacy of incobotulinumtoxinA in poststroke upper limb spasticity: results from a large multicenter 1-year noninterventional study (2015) (0)
- Dystonia Discomfort Scale (2019) (0)
- Efficacy of incobotulinumtoxinA for treatment of lower limb spasticity, including pes equinovarus, in adults (2018) (0)
- Manual of Botulinum Toxin Therapy: Developing the next generation of botulinum toxin drugs (2009) (0)
- 67. Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum neurotoxin therapy (2015) (0)
- An enzyme-linked immunosorbent assay for detection of botulinum toxin antibodies (2013) (0)
- Book Review / Announcement (2002) (0)
- Complexing proteins: Are they necessary for mechanical stability of botulinum toxin drugs? (2016) (0)
- Obituary: Dr Alan Brown Scott. (2022) (0)
This paper list is powered by the following services:
Other Resources About Dirk Dressler
What Schools Are Affiliated With Dirk Dressler?
Dirk Dressler is affiliated with the following schools:
